|
 |
AbataceptThis page contains recent news articles, when available, and an overview of Abatacept but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The National Rheumatoid Arthritis Society (NRAS) said its appeal had failed over the drug abatacept (Orencia) for the treatment of moderate to severe The Press Association Thousands of arthritis patients denied drug after treatment is ... - 23 Apr 2008 ..."Abatacept is not like other biologic agents as it works in a different way. NICE is effectively denying desperate patients any last hope of remission from Daily Mail, US Food and Drug Administration Approves ORENCIA(R) (abatacept ... - Apr 8, 2008 The approval is based on the AWAKEN (Abatacept Withdrawal study to Assess efficacy and safety in Key Endpoints in juvenile idiopathic arthritis Not FOXBusiness FDA Approval: Orencia - Apr 17, 2008 Identify a new indication for abatacept intravenous infusion. Describe the appropriate use of abatacept for the treatment of juvenile idiopathic arthritis. Medscape (subscription) FDA Approves Abatacept (Orencia) for Juvenile Idiopathic Arthritis - Apr 9, 2008 For juvenile idiopathic arthritis, IV abatacept was indicated as a monotherapy or together with methotrexate, the company said. MedPage Today, FDA Approves Abatacept for the Treatment of Polyarticular Juvenile ... - Apr 8, 2008 PRINCETON, NJ -- April 8, 2008 -- The US Food and Drug Administration (FDA) has approved abatacept (Orencia) for reducing signs and symptoms in paediatric DG News Bristol-Myers Squibb - Apr 22, 2008 The company recently announced that the US Food and Drug Administration (FDA) has approved ORENCIA(R) (abatacept) for reducing signs and symptoms in Zacks.com, Orencia gains JIA indication - Apr 9, 2008 The FDA has approved the use of Orencia (abatacept, from Bristol-Myers Squibb) for reducing signs and symptoms of moderately-to-severely active Prescribing Reference, Abbott Announces HUMIRA® (adalimumab) Approved In Japan For The ... - Apr 21, 2008 The combinations of HUMIRA and anakinra as well as HUMIRA and abatacept is not recommended. TNF antagonists, including HUMIRA, have been associated in rare Medical News Today (press release), Department of Medicine researcher mounts new attack on lupus - Mar 25, 2008 He recently recruited Jeffrey Ledbetter, PhD, a founder of the local biotechnology company Trubion and co-inventor of the biologic Abatacept (Orencia), WebWire (press release), ORENCIA Approved For Treatment Of Polyarticular Juvenile ... - Apr 10, 2008 FDA has approved Bristol-Myers Squibb's ORENCIA (abatacept) for reducing signs and symptoms in pediatric patients six years and older with moderately to eMaxHealth.com, Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the ... - Apr 16, 2008 The combinations of HUMIRA and anakinra as well as HUMIRA and abatacept is not recommended. TNF antagonists, including HUMIRA, have been associated in rare CNNMoney.com (press release) Bristol-Myers Says FDA Approved ORENCIA For Treatment Of ... - Apr 8, 2008 ...(BMY) announced that the US Food and Drug Administration has approved ORENCIA (abatacept) for reducing signs and symptoms in pediatric patients six years RTT News, Celebrity Chef Sandra Lee Offers Recipes and Shortcuts in the ... - Feb 28, 2008 ...(1) In this population, ORENCIA(R) (abatacept) is indicated to treat adults with moderately to severely active RA who have had an inadequate response to one FOXBusiness Watery Pools In Bone Marrow Key To Psoriatic Arthritic Damage - Mar 6, 2008 We can spare them the side effects and perhaps switch them to drugs like rituximab or abatacept, which are approved for rheumatoid arthritis patients that Science Daily (press release) Celebrity Chef Sandra Lee Offers Recipes and Shortcuts in the ... - Feb 27, 2008 ...makers of the RA treatment ORENCIA(R) (abatacept), and the Arthritis Foundation, to launch the I Can with RA in the Kitchen campaign. SunHerald.com, Unmet Needs Provide Challenges and Opportunities for Rheumatoid ... - Feb 26, 2008 Enbrel (etanercept; Wyeth/Amgen); Humira (adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera (rituximab; Roche/Biogen/Genentech); PR Newswire (press release), Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief ... - Feb 11, 2008 Immunology at Bristol-Myers Squibb, where he co-discovered and aided clinical development of immunomodulatory drugs abatacept (Orencia) and belatacept. Lifescience-online, B-MS posts loss and counts cost of subprime investments - Feb 1, 2008 ...rose to $56 million from $14 million in the fourth quarter last year, while Orencia (abatacept) for rheumatoid arthritis brought in $75 million, Pharma Times (subscription), Reed Hopeful On Arthritis Drugs Appeal - Jan 23, 2008 Loughborough MP Andy Reed has said that he hopes that an appeal will allow local arthritis sufferers in Loughborough have access to the Orencia (abatacept) Loughborough News, Comparative Effectiveness of Treatments for Rheumatoid Arthritis - Jan 14, 2008 Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients Annals of Internal Medicine HIV, Oncology Could See Promising New Therapies in Place in 2008 - Jan 16, 2008 Another Genentech product, Herceptin (trastuzumab), is in a combination trial with Avastin, says Gorman, and RA infusible Orencia (abatacept) may see a Atlantic Information Services, Inc., Bristol-Myers Squibb: makes move to cut costs - 19 Dec 2007 ...a monoclonal antibody (mAb) in Phase III clinical trials; and biologic Orencia (abatacept), launched for the treatment of rheumatoid arthritis in 2006. Trading Markets (press release), FDA Approves Celltrion to Manufacture ORENCIA(R) (abatacept) - Dec 18, 2007 ...to produce ORENCIA(R) (abatacept), a novel biologic agent for the treatment of rheumatoid arthritis, developed by Bristol-Myers Squibb Company . CNNMoney.com Drug Combos Effective Against Rheumatoid Arthritis - Nov 26, 2007 Biologic DMARDs include abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), etanercept (Enbrel), infliximab (Remicade) and rituximab (Rituxan). Washington Post, Little difference among rheumatoid arthritis drugs - Nov 20, 2007 They also looked at biological dmards such as abatacept, made by Bristol-Myers Squibb Co. under the brand name Orencia; adalimumab, sold by Abbott Tehran Times, Combining Medications Often Best Strategy To Battle Rheumatoid ... - Nov 20, 2007 Synthetic DMARDS include hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine; biologic DMARDS include abatacept, adalimumab, anakinra, Science Daily (press release) Post-Hoc Data Show Daily Activity Participation, Independence and ... - Nov 12, 2007 These data are from post-hoc analyses of two Phase III pivotal trials investigating ORENCIA: AIM (Abatacept in Inadequate responders to Methotrexate) and CNNMoney.com Five-Year Data Demonstrate Long-Term Efficacy and Safety with ... - Nov 9, 2007 The primary endpoint of the double-blind portion of the study was ACR 20 at 6 months (60 percent for ORENCIA(R) (abatacept) vs. 35.5 percent for placebo). CNNMoney.com Drugs Can Ease Juvenile Rheumatoid Arthritis - Nov 9, 2007 One study found that abatacept, used to treat adults with moderate to severe rheumatoid arthritis, may be a well-tolerated treatment for children and Washington Post, NICE rules out abatacept for arthritis patients - Oct 26, 2007 The rheumatoid arthritis (RA) drug abatacept is too expensive to be prescribed on the NHS, according to NICE. In a draft single technology appraisal of the Healthcare Republic NHS patients denied arthritis drug - Oct 25, 2007 The National Institute for Clinical Excellence (NICE) has said it will not reconsider its recommendation in August not to prescribe abatacept (known as Guardian Unlimited, Arthritis sufferers' anger as drug is denied on NHS - Oct 25, 2007 The National Institute for Clinical Effectiveness (Nice) said the drug abatacept (Orencia) showed strong evidence of clinical benefit but its price, Independent, Bristol-Myers says Orencia shows 'long-term efficacy and safety' - Nov 9, 2007 ...(NYSE:BMY PR) (NYSE:BMY) said Friday that five-year data on Orencia (abatacept) demonstrates 'long-term efficacy and safety' in adult rheumatoid arthritis CNNMoney.com Arthritis Care - Oct 26, 2007 Abatacept is licensed in the UK for use in combination with methotrexate for adults with active moderate to severe RA, who have responded poorly to other FemaleFirst.co.uk, Pulling of arthritis drug a 'huge blow' - Nov 2, 2007 By Greg Baxter A decision by UK’s pharmaco-economic watchdog to refuse patients with severe rheumatoid arthritis the use of the drug Abatacept must be Irish Medical Times, Arthritis treatment denied - Oct 25, 2007 Health campaigners have reacted with dismay to the news that the drug abatacept (Orencia) has not been advised for people with arthritis. InTheNews.co.uk, NICE arthritis ruling 'will dash the hopes of thousands' - Oct 26, 2007 By Lilian Anekwe nice's decision not to approve the funding of abatacept will ‘dash the hopes of thousands of patients’ with severe rheumatoid arthritis, Pulse, NICE guidance "snubs" rheumatoid arthritis patients - Oct 26, 2007 Abatacept was a bright, new hope for them, and to put it beyond their reach will seem catastrophic. "People qualified to receive anti-TNF treatment already OnMedica, Britain rejects arthritis drug - Oct 26, 2007 LONDON, Oct. 27 (UPI) -- Britain's National Health Service has rejected the drug abatacept for severe arthritis sufferers because the cost is too high. United Press International Return to form for Plavix propels profits at Bristol-Myers Squibb - Oct 26, 2007 ...rose to $46 million from $11 million in the third quarter last year, while Orencia (abatacept) for rheumatoid arthritis brought in $76 million, Pharma Times (subscription), Bristol-Myers Squibb Says Phase III Trials Of ORENCIA In RA ... - Nov 12, 2007 ...on Monday said that the results from two Phase III pivotal trials showed ORENCIA or abatacept improved daily activity participation, physical and Trading Markets (press release), Girls of 12 to receive cancer virus vaccine - Oct 25, 2007 The drugs advisory body Nice ruled yesterday that the drug abatacept should not be given to treat an aggressive form of rheumatoid arthritis. Telegraph.co.uk, Anti-CD20 Drugs: Magic Bullet In Treating 'Enigmatic' Lupus? - Nov 2, 2007 ...epratuzumab, from Immunomedics Inc.; atacicept, from zymogenetics Inc. and Merck Serono; and Orencia (abatacept), from Bristol-Myers Squibb Co. BioWorld Online, While RA Bids Line Runway, Poll Finds Unhappy Patients - Oct 26, 2007 ...s anti-B cell therapy Orencia (abatacept), he noted, adding that he was making a more general point. "You don't even have to go to those specific BioWorld Online, What Are The Pitfalls Of Current Treatment For Rheumatoid Arthritis - Sep 29, 2007 Abatacept differs from other disease-modifying treatments in that it has a different mechanism of action. This therapy blocks costimulation which is a major PR-GB.com (press release), Morning newspapers - 2 October 2007 - Oct 2, 2007 Abatacept reportedly puts a brake on the disease and stops it from further affecting the joints. It is primarily intended for patients who no longer respond Expatica Netherlands, Adnexus Nixes IPO Route, Opts For $430M BMS Exit - Sep 24, 2007 He noted that BMS has two biological products on the market: Orencia (abatacept), a product to treat rheumatoid arthritis, and Erbitux (cetuximab), BioWorld Online, ORENCIA(R) (abatacept) Supplemental Biologics License Application ... - Aug 8, 2007 It is not known if ORENCIA(R) (abatacept) can harm an unborn baby. Women who are breast feeding should also inform their doctor. They will need to decide to Medical News Today (press release), Arthritis Research Campaign: Nice decision is excellent news - Aug 22, 2007 It follows an earlier decision by the government's medicines regulator to not recommend Abatacept (Orencia) for arthritis treatment on the NHS for reasons InTheNews.co.uk, Saving Self - Sep 5, 2007 ...“T cells play an integral role in autoimmunity,� says Michael Corbo, PhD, RPh, vice president of development for Orencia (abatacept) at Bristol-Myers Squibb Drug Discovery & Development, Payers May See Higher Costs for Lupus as New Therapies Emerge - Aug 28, 2007 In addition to Rituxan, Medco's 2007 Drug Trend Report lists the RA drug Orencia (abatacept) and the immunosuppressant drug CellCept (mycophenolate mofetil) Atlantic Information Services, Inc., Early diagnosis is key to rheumatoid arthritis treatment - Aug 24, 2007 But new biologic DMARDs, including abatacept, which works early to block the inflammatory process, and rituximab, which down-regulates inflammatory cells Daily Mail, Charity applauds arthritis drug law - Aug 24, 2007 ..."It's particularly welcome given NICE's recent draft guidance that another drug for severe rheumatoid arthritis, abatacept (Orencia), was too expensive." Charities Aid Foundation, Charity hails NICE's backing for Roche's MabThera in arthritis - Aug 22, 2007 The news comes less than three weeks after NICE issued draft guidance rejecting another anti-TNF therapy, Bristol-Myers Squibb’s Orencia (abatacept) for Pharma Times (subscription), Report Highlights Impact of Recent Entries and New Mechanisms on ... - Aug 16, 2007 Enbrel (etanercept; Wyeth/Amgen); Humira (adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera (rituximab; Roche/Biogen/Genentech); PharmaLive.com (press release), Stock on the Move for Tuesday: BQTG! August 14, 2007 - Aug 14, 2007 ...for filing and review, the supplemental biologics license application (sBLA) for ORENCIA® (abatacept) for the treatment of pediatric patients with Web Services Journal, Doctor's diary - Aug 5, 2007 Telegraph.co.uk,Hence the rumpus this week about the new treatment for rheumatoid arthritis, abatacept (Orencia), as discussed in the feature, left, which the regulatory Pain relief drug ruled too costly for the NHS - Aug 1, 2007 Times Online,Abatacept, which has the brand name Orencia, is the latest of a new generation of drugs to be blocked by NICE on the ground that it is not cost-effective. Arthritis patients denied new drug - Aug 1, 2007 Guardian Unlimited,The health watchdog, the National Institute for Health and Clinical Excellence (Nice), is publishing draft guidance that does not recommend abatacept Watchdog rules out arthritis drug on NHS - Aug 1, 2007 Guardian Unlimited,The body responsible for deciding what medication should be available on the NHS said abatacept, manufactured by Bristol-Myers Squibb under the brand name UK body says Bristol-Myers Orencia drug too costly - Aug 1, 2007 Reuters.uk,..."Having examined the cost effectiveness analyses on abatacept against a range of comparators, the committee concluded that abatacept could not be considered Update on Biologic Therapies From EULAR 2007 - Aug 3, 2007 Medscape (subscription)Both abatacept (in a study known as the Abatacept Trial in Treatment of Anti-TNF INadequate responders [ATTAIN]) and rituximab (in a study known as the Arthritis drug decision slammed - Aug 1, 2007 Channel 4 News,The National Institute for Health and Clinical Excellence (Nice) published draft guidance saying abatacept (Orencia) should not be used on the NHS for Arthritis drug 'blocked for NHS' - Aug 2, 2007 BBC News,Ailsa Bosworth, chief executive of NRAS, said it would be wrong to deny this group the option of taking Orencia (technical name: abatacept). NICE rules arthritis drug too costly - Aug 2, 2007 OnMedica,The National Institute for Health and Clinical Excellence (NICE) has ruled that the arthritis drug abatacept (Orencia) is not cost-effective in draft Arthritis Sufferers In For More Discomfort - Aug 2, 2007 MedIndia,According to the National Institute for Health and Clinical Excellence (Nice) arthritis drug abatacept (Orencia) should not be used by the NHS for people Arthritis patients may not get drug - Aug 2, 2007 Nursing in Practice,The National Institute for Health and Clinical Excellence (NICE) has published draft guidance that does not recommend Orencia (abatacept) on the NHS for BMS’ arthritis drug Orencia knocked back by NICE - Aug 2, 2007 Pharma Times (subscription),Orencia (abatacept) is the first in class of so-called selective T-cell co-stimulation modulators that is designed to block a signal required in the Soldier DIES IN ROADSIDE BLAST IN IRAQ - Aug 1, 2007 Mirror.co.uk,Angry arthritis sufferers could be denied a new drug abatacept on the NHS after the National Institute for Health and Clinical Excellence (Nice) ruled it Seven days - Aug 4, 2007 Times Online,...thousands of patients with severe rheumatoid arthritis were told that they would not be allowed treatment with the drug Orencia (abatacept) because of Bristol-Myers Squibb: Orencia is rejected by NICE in the UK - Aug 3, 2007 Pharmaceutical Business Review...which was made over grounds of Orencia (abatacept) not being cost-effective, is only a preliminary judgment and the final decision to fund the therapy : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |